Gemifloxacin is a quinolone antibacterial agent used for the treatment of acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia caused by susceptible bacteria. It is available in oral formulations.
- Mechanism
- Curator reviewed
The bactericidal action of gemifloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination.
- Primary indication
- For the treatment of bacterial infection caused by susceptible strains such as S. pneumoniae, H. influenzae, H. parainfluenzae, or M. catarrhalis, S. pneumoniae (including multi-drug resistant strains [MDRSP]), M. pneumoniae, C. pneumoniae, or K. pneumoniae.Curator reviewed · 6 structured indications
- Formula / weight
- C18H20FN5O4 · 389.3809 g/mol (avg)
- First approval
- Canada, 2004 · United States, 2003
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
ZRCVYEYHRGVLOC-HYARGMPZSA-NSMILESCO\N=C1/CN(CC1CN)C1=NC2=C(C=C1F)C(=O)C(=CN2C1CC1)C(O)=OWhat you can answer from here — as of September 23, 2026
4Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Gemifloxacin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account